EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Marina Vivarelli, Jonathan Barratt, Laurence H Beck, Fadi Fakhouri, Daniel P Gale, Elena Goicoechea de Jorge, Marta Mosca, Marina Noris, Matthew C Pickering, Katalin Susztak, Joshua M Thurman, Michael Cheung und 5 weitere

Kidney International · 2024-09 · 106 (3) · 369-391

DOI: 10.1016/j.kint.2024.05.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2024-09. Verfasst von Marina Vivarelli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nephrology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: marina.vivarelli@opbg.net. Hauptthemen laut MEDLINE: Complement Activation, Kidney Diseases. Die Arbeit wurde bisher 153-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uncontrolled complement activation can cause or contribute to glomerular injury in multiple kidney diseases. Although complement activation plays a causal role in atypical hemolytic uremic syndrome and C3 glomerulopathy, over the past decade, a rapidly accumulating body of evidence has shown a role for complement activation in multiple other kidney diseases, including diabetic nephropathy and several glomerulonephritides. The number of available complement inhibitor therapies has also increased during the same period. In 2022, Kidney Diseases: Improving Global Outcomes (KDIGO) convened a Controversies Conference, "The Role of Complement in Kidney Disease," to address the expanding role of complement dysregulation in the pathophysiology, diagnosis, and management of various glomerular diseases, diabetic nephropathy, and other forms of hemolytic uremic syndrome. Conference participants reviewed the evidence for complement playing a primary causal or secondary role in progression for several disease states and considered how evidence of complement involvement might inform management. Participating patients with various complement-mediated diseases and caregivers described concerns related to life planning, implications surrounding genetic testing, and the need for inclusive implementation of effective novel therapies into clinical practice. The value of biomarkers in monitoring disease course and the role of the glomerular microenvironment in complement response were examined, and key gaps in knowledge and research priorities were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement ActivationKidney DiseasesHumansBiomarkersComplement Inactivating AgentsComplement System ProteinsCongresses as TopicDisease ProgressionKidney Glomerulus

Stichwörter der Autor:innen

complement inhibitorcomplement-mediated injuryglomerular injury

Substanzen

BiomarkersComplement Inactivating AgentsComplement System Proteins

Autor:innen und Institutionen

  • Laboratory of Nephrology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: marina.vivarelli@opbg.net.
  • Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Department of Nephrology, Centre Hospitalier Universitaire, Nantes, France; INSERM UMR S1064, Nantes, France.
  • Centre for Kidney and Bladder Health, University College London, UK.
  • Department of Immunology, Ophthalmology and ORL, Complutense University, Madrid, Spain; Area of Chronic Diseases and Transplantation, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.

Förderung

  • Wellcome Trust

Zitieren

APA

Vivarelli, M., Barratt, J., Beck, L. H., Fakhouri, F., Gale, D. P., Goicoechea de Jorge, E., Mosca, M., Noris, M., Pickering, M. C., Susztak, K., Thurman, J. M., Cheung, M., King, J. M., Jadoul, M., Winkelmayer, W. C., Smith, R. J. H., & for Conference Participants (2024). The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 106(3), 369-391. https://doi.org/10.1016/j.kint.2024.05.015

Vancouver

Vivarelli M, Barratt J, Beck LH, Fakhouri F, Gale DP, Goicoechea de Jorge E, et al. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2024;106(3):369-391. doi:10.1016/j.kint.2024.05.015

BibTeX
@article{Vivarelli2024,
  author = {Vivarelli, Marina and Barratt, Jonathan and Beck, Laurence H and Fakhouri, Fadi and Gale, Daniel P and Goicoechea de Jorge, Elena and Mosca, Marta and Noris, Marina and Pickering, Matthew C and Susztak, Katalin and Thurman, Joshua M and Cheung, Michael and King, Jennifer M and Jadoul, Michel and Winkelmayer, Wolfgang C and Smith, Richard J H and for Conference Participants, for Conference Participants},
  title = {The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference},
  journal = {Kidney International},
  year = {2024},
  volume = {106},
  number = {3},
  pages = {369--391},
  doi = {10.1016/j.kint.2024.05.015}
}
Kostenlos starten →